Casopitant (INN), former tentative trade names Rezonic (U.S.) and Zunrisa (Europe), is an NK1 receptor antagonist which was undergoing research for the treatment of chemotherapy-induced nausea and vomiting. It was under development by GlaxoSmithKline. In July 2008, the company filed a marketing authorisation application with the European Medicines Agency. The application was withdrawn and development was discontinued in September 2009 because GlaxoSmithKline decided that further safety assessment was necessary. However, a 2022 review listed casopitant as under development as a potential novel antidepressant for the treatment of major depressive disorder, with a phase 2 clinical trial having been completed.
Property | Value |
---|---|
dbo:abstract |
|
dbo:casNumber |
|
dbo:chEMBL |
|
dbo:fdaUniiCode |
|
dbo:kegg |
|
dbo:pubchem |
|
dbo:thumbnail | |
dbo:wikiPageID |
|
dbo:wikiPageLength |
|
dbo:wikiPageRevisionID |
|
dbo:wikiPageWikiLink |
|
dbp:atcPrefix |
|
dbp:atcSuffix |
|
dbp:c |
|
dbp:casNumber |
|
dbp:chembl |
|
dbp:chemspiderid |
|
dbp:f |
|
dbp:h |
|
dbp:iupacName |
|
dbp:kegg |
|
dbp:n |
|
dbp:o |
|
dbp:pubchem |
|
dbp:smiles |
|
dbp:stdinchi |
|
dbp:stdinchikey |
|
dbp:synonyms |
|
dbp:unii |
|
dbp:verifiedrevid |
|
dbp:watchedfields |
|
dbp:width |
|
dbp:wikiPageUsesTemplate | |
dcterms:subject | |
gold:hypernym | |
rdf:type |
|
rdfs:comment |
|
rdfs:label |
|
owl:sameAs | |
prov:wasDerivedFrom | |
foaf:depiction | |
foaf:isPrimaryTopicOf | |
is dbo:wikiPageRedirects of | |
is dbo:wikiPageWikiLink of | |
is foaf:primaryTopic of |